National uniformity for OTCs should be a priority in 105th Congress, Sen. Hatch says.
This article was originally published in The Tan Sheet
Executive Summary
NATIONAL UNIFORMITY FOR OTC DRUGS should be a priority in the 105th Congress, Sen. Orrin Hatch (R-Utah) said in a Sept. 30 floor statement on FDA reform efforts in the 104th session. "[An] issue that I would like to see addressed next year is one that has been periodically on the FDA radar screen -- the issue of national uniformity in regulation of products that fall within FDA's purview," Hatch stated.